Cargando…
Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis
APX001 is a first-in-class, intravenous and orally available, broad-spectrum antifungal agent in clinical development for the treatment of life-threatening invasive fungal infections. The half-life of APX001A, the active moiety of APX001, is significantly shorter in mice than in humans (1.4 to 2.75...
Autores principales: | Zhao, Yanan, Lee, Min Hee, Paderu, Padmaja, Lee, Annie, Jimenez-Ortigosa, Cristina, Park, Steven, Mansbach, Robert S., Shaw, Karen Joy, Perlin, David S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153843/ https://www.ncbi.nlm.nih.gov/pubmed/30012766 http://dx.doi.org/10.1128/AAC.00425-18 |
Ejemplares similares
-
In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
por: Hager, Christopher L., et al.
Publicado: (2018) -
Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis
por: Wiederhold, Nathan P., et al.
Publicado: (2019) -
In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
por: Shaw, Karen Joy, et al.
Publicado: (2018) -
Differential Regulation of Echinocandin Targets Fks1 and Fks2 in Candida glabrata by the Post-Transcriptional Regulator Ssd1
por: Healey, Kelley R., et al.
Publicado: (2020) -
Evaluation of the In Vitro and In Vivo Antifungal Activity of APX001A/APX001 Against Candida auris
por: Larkin, Emily, et al.
Publicado: (2017)